How much do you know about the use of PET/CT imaging to manage multiple myeloma? Take our latest quiz to test your knowledge.
In our May multiple myeloma quiz, you'll get a chance to test your knowledge of the use of PET/CT imaging in patients with multiple myeloma. Here's your first question:
1. Flourine-18 (18F)-fluorodeoxyglucose (FDG) PET/CT imaging can be performed for which of the following?
A.Staging multiple myelomaB.Evaluating treatment responseC.Detecting intramedullary and extramedullary diseaseD.All of the above
Answer: D. All of the above. FDG PET/CT is increasingly seen as an important tool in diagnosing, prognosticating, and monitoring multiple myeloma. FDG PET/CT has been performed to stage myeloma at diagnosis, to evaluate treatment responses and relapse, and to detect both intramedullary and extramedullary disease.
2. The gold standard for image-based assessment of diffuse bone marrow involvement, pathologic fracture characterization, and spinal cord compression in patients with multiple myeloma is:
A.PETB.FDG PET/CTC.MRID.Dual-energy CT (DECT)
Answer: C. MRI. While FDG PET/CT has been reported to offer an overall sensitivity of 90% with a specificity of 75%, MRI, an imaging modality that does not involve ionizing radiation, remains the gold standard for sensitive detection and assessment of diffuse bone marrow involvement and spinal cord compression. MRI is also considered to be optimal for characterizing pathologic bone fracture.
3. Which of the following is considered optimal for extramedullary disease assessment in multiple myeloma?
Answer: B. FDG PET/CT. FDG PET/CT is considered optimal for assessing extramedullary disease in patients with multiple myeloma. However, it is relatively costly compared with CT and MRI, can be suboptimal for assessing diffuse marrow involvement, and can yield false-positive results at bone marrow biopsy sites.
4. FDG PET/CT is useful in identifying which of the following in multiple myeloma?
A.Intramedullary diseaseB.Extramedullary diseaseC.Both A and BD.None of the above
Answer: C. Both A and B. Therapy response assessment in multiple myeloma depends importantly on measuring plasma cell–secreted monoclonal protein levels in serum or urine, but FDG PET/CT is useful in identifying both intramedullary and extramedullary disease.
5. FDG PET/CT is useful in assessing treatment response and detecting disease progression in the following setting(s):
A.Solitary plasmacytomaB.Nonsecretory multiple myelomaC.Relapsed multiple myelomaD.All of the above
Answer: D. All of the above. FDG PET/CT is used to assess disease response to treatment among patients with solitary plasmacytoma, nonsecretory multiple myeloma, and those undergoing first-line therapy or second- or third-line therapies for relapsed multiple myeloma.